Characterization of the Sch9 Longevity Pathway in Yeast
Description: Project Narrative The primary causes of death in developed countries are type 2 diabetes, cancer, cardiovascular and immunological dysfunctions, and neurodegeneration, the so called age-related diseases. Our studies are the first to show that treating yeast cells (Saccharomyces cerevisiae) with the drug myriocin, which targets the first step in the evolutionarily conserved sphingolipid synthesis pathway, can be used to slow aging and increase lifespan. This novel strategy has the potential to reduce the incidence and slow the onset of age-related diseases in humans and improve health span.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R56
Start date: 2004-09-01
End date: 2019-08-31
Investigator: ROBERT CARL DICKSON
Institution: UNIVERSITY OF KENTUCKY
Subfield: Aging
Domain: Life Sciences
Funded outputs count: 10
Funder award ID: R56AG024377
OpenAlex ID: G7952485915